X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
The partnership aims to develop and commercialise of Rivalif (rivastigmine) twice weekly transdermal patch in South Korea for the treatment of mild to moderate dementia associated with Alzheimer's disease.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Rivalif
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Myung In Pharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 05, 2024
Details:
Rivastigmine MD (rivastigmine) is an acetylcholinesterase inhibitor, transdermal patch. It is approved for the treatment of mild to moderate Alzheimer's Disease.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Rivastigmine MD
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gensci
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
Rivastigmine patch is a class of medications called cholinesterase inhibitors, which is used to manage and treat neurodegenerative disease, specifically dementia, in patients with Alzheimer and Parkinson disease.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2023
Details:
Exelon Patch (rivastigmine transdermal system) is a class of medications called cholinesterase inhibitors, which is used to manage and treat neurodegenerative disease, specifically dementia, in patients with Alzheimer and Parkinson disease.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Exelon
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Details:
Rivastigmine MD (rivastigmine) is an acetylcholinesterase inhibitor, transdermal patch. It is approved for the treatment of mild to moderate Alzheimer's Disease.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Rivastigmine MD
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gensci
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
Details:
Through the agreement, the company grants Exeltis exclusive rights to commercialize the Rivastigmine MD (rivastigmine), a multi-day transdermal patch for the treatment of Alzheimer’s disease.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Rivastigmine MD
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Exeltis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 31, 2022
Details:
Through the agreement, the company grants Gensci exclusive rights to commercialize the Rivastigmine MD (rivastigmine), a multi-day transdermal patch for the treatment of Alzheimer’s disease.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Rivastigmine MD
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gensci
Deal Size: $33.9 million Upfront Cash: $10.9 million
Deal Type: Agreement December 22, 2021
Details:
Through the agreement, the company grants Zambon exclusive rights to commercialize Rivalif (rivastigmine), a multi-day transdermal patch for the treatment of Alzheimer’s disease.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Rivalif
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zambon Group SpA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 10, 2021
Details:
Zeyzelf (rivastigmine) is an acetylcholinesterase inhibitor, transdermal patch. It is approved for the treatment of mild to moderate Alzheimer's Disease.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Zeyzelf
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2021
Details:
Rivastigmine MD (rivastigmine) is an acetylcholinesterase inhibitor, transdermal patch. It is approved for the treatment of mild to moderate Alzheimer's Disease.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Rivalif
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2021
Details:
Under the terms of the agreement, Italfarmaco gains the exclusive rights to commercialize Rivastigmine MD in Germany, Italy, Portugal and Greece. Italfarmaco will also have a preferred right to market Rivastigmine MD in Chile and Vietnam.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Rivastigmine MD
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Luye Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 16, 2021
Details:
According to the agreement, Luye Pharma has granted Towa the exclusive rights to develop and commercialize Rivastigmine MD in Japan.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Rivastigmine MD
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Towa Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 18, 2021
Details:
Rivastigmine is an acetylcholinesterase inhibitor. It's once a day transdermal patch is approved for the treatment of mild to moderate Alzheimer's Disease.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2021
Details:
It is the first transdermal patch product approved for marketing under China CDE’s quality and efficacy consistency evaluation. Rivastigmine Transdermal Patch works by delivering medication through the epidermis and dermis to the dermal layer.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020
Details:
Rivalif (rivastigmine) is an acetylcholinesterase inhibitor, transdermal patch. It is being developed for the treatment of mild to moderate Alzheimer's Disease.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Rivalif
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
